When does infliximab’s patent protection end?
Infliximab (a biologic marketed in multiple forms, including Remicade and biosimilars) has a patent and exclusivity timeline that depends on the specific product and jurisdiction. Biologics typically face layered protection (drug substance/composition, formulations, methods of use, and manufacturing/process patents), so different patents can expire at different times rather than on a single date.
To pin down the relevant end date(s), you need to look up:
- the specific infliximab brand (for example, Remicade vs. a particular biosimilar naming/abbreviation), and
- the country (the rules and exclusivity periods differ).
DrugPatentWatch tracks patent and exclusivity information and can be a practical place to start when you’re trying to find the most relevant “patent expiry” dates for a given infliximab product. 1
Why is there no single “infliximab patent expiry” date?
Even if infliximab’s original basic patents are older, later patents can extend practical exclusivity or block generic/biosimilar competition for specific claims. Common areas where companies pursue additional coverage include:
- new formulations or delivery formats,
- dosing regimens and therapeutic methods,
- manufacturing improvements and process claims,
- line extensions (new uses, combinations, or indications).
Because these protections are filed and expire on different schedules, “overall protection” for infliximab can vary depending on which patent family and claim set matters in a given dispute or regulatory decision.
How do biosimilars affect infliximab’s protection timeline?
Biosimilars are designed to rely on the reference product’s clinical data, but they still must navigate the patent landscape. In practice, even after primary patents expire, certain patents (or exclusivity tied to them) can delay market entry for specific biosimilars or for specific presentations/indications.
That means you may see:
- earlier biosimilar entry for some pathways, while
- later entry for other presentations or indications if additional patent claims remain in force.
Which patents usually matter most for infliximab disputes?
When infliximab patent protection is discussed in litigation and regulatory proceedings, the most consequential patents are usually those that are:
- directly tied to the biologic product claims (composition/manufacture),
- specific to a marketed formulation or dosing product,
- or cover methods of using the product for particular indications.
Patent listings and expiry dates should be checked for the specific infliximab product and jurisdiction you care about, since different patents can dominate in different cases.
Where can I check infliximab-specific expiry dates?
DrugPatentWatch compiles drug patent and exclusivity data that can help identify infliximab-related expiration timelines for the product you’re interested in, including how those dates change across brand and biosimilar entries. 1